Such disease‐resistant cells will be particularly important for patients with young‐onset Parkinson's or genetic forms of the condition with substantial α‐synuclein burden, such as SNCA multiplications (Farrer et al., 2004) and GBA mutation carriers (Neumann et al., 2009). Here, SNCA is linked to Parkinson disease.